YERVOY® (ipilimumab)

Patient
Alert Card

YERVOY® (ipilimumab)

This card has important information.

Always carry this Alert Card with you and show it to any doctor you may need to see (for example, if your regular doctor is unavailable or you are travelling).



Tell your doctor right away if you experience any of these symptoms or any other symptoms.

 BOWEL AND STOMACH¹ diarrhoea (watery, loose or soft stools), bloody or dark-coloured stools more frequent bowel movements than usual pain or tenderness in your stomach or abdomen area, nausea, vomiting 	 e redness in the eye pain in the eye vision problems or blurry vision 	 Report any of these symptoms to your doctor right away. Symptoms that may appear mild can quickly worsen if left untreated.¹ Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped, allowing you to get the maximum benefit from treatment. Signs and symptoms may be delayed and may occur weeks to months after your last injection.¹ Don't try to treat these symptoms yourself without consulting with your doctor first. Carry this card and show to ANY doctor you might interact with, and say that you are being treated with ipilimumab.
• eye or skin yellowing (jaundice) • pain on the right side of your stomach area • dark urine	NERVES¹ • muscle weakness • numbness or tingling in legs, arms or face • dizziness, loss of consciousness or difficulty waking up	
• skin rash with or without itching, dry skin • blisters and/or peeling of the skin, mouth sores • swelling of the face or lymph glands	 GENERAL¹ fever, headache, tiredness bleeding behavioural changes (e.g. less sex drive, being irritable or forgetful) 	

You can get more information in the YERVOY® Package Leaflet: www.ema.europa.eu

My physician's contact information

Name of Physician Office Phone After-hours Phone

My Name and Phone Name and Phone of Caregiver (in case of emergency)

i IMPORTANT information for healthcare providers

- This patient is treated with YERVOY®.
- Immune-related Adverse Reactions (irARs) can mostly occur during the treatment period, but may appear months after the last dose of YERVOY[®].
- Early diagnosis and appropriate management are essential to minimise life-threatening complications. YERVOY® specific management guidelines for irARs are available.
- If you are a doctor not specialised in oncology, please contact a specialist.

Healthcare providers please consult the YERVOY® Summary of Product Characteristics at www.ema.europa.eu or call Bristol-Myers Squibb Medical Information at 00 356 2397 6505 for more information.

1. YERVOY® Package Leaflet.